-
Posted by
Two Blokes Mon at 8:30 PM -
Filed in
Stock
-
2 views
Data from phase 1 studies using SC291 to treat patients with B-cell mediated autoimmune disorders and SC262 for patients with relapsed/refractory B-cell malignancies expected in 2025. First-in-human study using UP421 as a HIP-modified primary islet cell therapy to treat patients with Type 1 Diabetes established increase circulating C-peptide biomarker and without need of immunosuppressive therapy. An IND filing to initiate a phase 1 study using SC451 for the treatment of patients with Type 1 Diabetes, expected in 2026.
